Cortexyme (CRTX) Upgraded by Zacks Investment Research to Hold

Cortexyme stock has undergone multiple analysts rating changes in the recent past.  Cortexyme Upgraded by Zacks Investment Research on 10-11-21. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

Shares of Cortexyme traded down -$8.88 on Monday, reaching $78.61. 251921 shares of the stock traded hands, compared to its average volume of 238231. Shares of Cortexyme were trading at $78.61 on Monday. The firm’s 50 day moving average is $90.40 and its 200 day moving average is $53.51.Cortexyme has a 12 month low of $78.59 and a 12 month high of $121.98. While on yearly highs and lows, Cortexyme’s today has traded high as $89.94 and has touched $78.59 on the downward trend. See More Analyst Rating at: RATING

Cortexyme Earnings and What to expect: 

Cortexyme last posted its earnings data on August 9th, 2021. The biopharmaceutical company reported ($0.74) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.05. Cortexyme has generated ($2.63) earnings per share over the last year (($2.94) diluted earnings per share). Earnings for Cortexyme are expected to grow in the coming year, from ($2.95) to ($2.68) per share. Cortexyme has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 11th, 2021 based off prior year’s report dates.

Earnings for Cortexyme are expected to grow in the coming year, from ($2.95) to ($2.68) per share. The P/E ratio of Cortexyme is -26.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Cortexyme is -26.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Cortexyme has a P/B Ratio of 13.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Cortexyme (CRTX) Moving Average Technical Analysis

5 day Moving Average is $88.20 And 5 day price change is -$18.17 (-18.77%)  with average volume for 5 day average is 275,680. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $89.81 and 20 day price change is -$8.58 (-9.84%) and average 20 day moving volume is 244,905. 50 day moving average is $90.40  and 50 day price change is $22.10 ( 39.11%)  and with average volume for 50 days is : 301,654. 200 day moving average is $53.51  and 200 day price change is $49.11 (166.47%)  and with average volume for 200 days is : 262,826.

Other owners latest trading in Cortexyme :

  • On 9/17/2021 shares held by Virtu Financial LLC were 5,397 which equates to market value of $0.29M and appx 0.00% owners of Cortexyme
  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 7,236 which equates to market value of $0.38M and appx 0.00% owners of Cortexyme
  • On 8/25/2021 shares held by Marshall Wace LLP were 38,651 which equates to market value of $2.05M and appx 0.00% owners of Cortexyme
  • In total Institutional ownership equates to Institutional Ownership Percentage: 61.84% for Cortexyme

See More Analyst Rating at: RATING